Quick Takeaways:
- Cronus Pharma has launched Robenacoxib Injection, the only FDA-approved bioequivalent to Onsior (robenacoxib) Injection in the US.
- The injection is indicated for postoperative pain and inflammation following soft tissue surgery in dogs and orthopedic surgery, ovariohysterectomy and castration in cats, for animals aged 4 months and older. Treatment is limited to a maximum of 3 days.
- Available as a 20 mg/mL solution in a 20 mL multidose vial, Robenacoxib Injection is now offered through veterinary distributors nationwide. Approved under ANADA #200-804, the launch expands Cronus Pharma’s portfolio of FDA-approved veterinary medicines while providing practices with greater treatment choice and value.
Why It Matters?
Cronus Pharma’s launch of Robenacoxib Injection gives US veterinarians the first FDA‑approved bioequivalent to Onsior (robenacoxib) Injection, providing a cost‑effective, short‑term NSAID option for postoperative pain and inflammation in dogs (soft‑tissue surgery) and cats (orthopedic surgery, OHE, castration) ≥4 months, for up to 3 days. 1139 As a 20 mg/mL, 20 mL multidose vial distributed nationally, it can help practices lower drug spend and diversify supply versus the branded product, while expanding Cronus’ portfolio of FDA‑approved veterinary generics in a competitive perioperative analgesia market.
Source: Businesswire
